Back to Screener

Healthcare

Terumo Corporation(TRUMF)

Live Price

Offline

$14.62

+0.00% today

1Y Change

-9.75%

Window

Jun 20, 2025 โ†’ Jun 12, 2026

Market Cap
$2.93T
Revenue Growth
+12.4%
EPS Growth
+10.5%
Dividend Yield
1.5%

Coverage: 246 bars ยท Jun 20, 2025 โ†’ Jun 12, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Terumo Corporation (TRUMF) is a Healthcare stock with a market cap of $2.93T and listed on OTC. The stock last traded around $14.62 and down 9.8% across the available one-year price window (Jun 20, 2025 โ†’ Jun 12, 2026). Baseline metrics include revenue growth of +12.4%, EPS growth of +10.5%, a dividend yield of 1.5%. What stands out right now is revenue +12.4%, EPS +10.5%, free cash flow +90.1% with operating margin 17.2% and ROIC 7.1%. The dividend is present but secondary, with a yield around 1.5%. Valuation is more restrained than many high-expectation growth names at P/E 22.9 and price/sales 2.7. Stock Foundry combines TRUMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+12.4% vs +7.6% peer median

Operating Margin

Below sector median

+17.2% vs +19.4% peer median

P/E

Below sector median

22.9 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 19, 2026, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +12.4% and EPS at +10.5%, with operating margin around 17.2%.

The next real check-in already has a date

The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 2 reported quarters, the stock averaged +13.7% over the next 5 trading days and finished higher after 1 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
May 19, 2026
โ€”+0.0%+27.4%โ€”
2026
May 15, 2026
+19.0%+0.0%+0.0%โ€”

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

TRUMF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

TRUMF Max Drawdown

-43.09%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for TRUMF and SPY.

Calendar-year return history is still loading or unavailable.
Terumo Corporation logo

Company Overview

Terumo Corporation

Other OTC

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

Leadership
Hikaru Samejima
IPO Date
Apr 13, 2011
Employees
30.2k
Street Address
2-44-1, Hatagaya
Mailing
Tokyo, 151-0072
Region
Tokyo, JP
Reporting Currency
USD
Investor Line
81 3 3374 8111
Last Updated
May 5, 2026
ISIN: JP3546800008
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
22.9
EV/EBITDA
11.6
Price/Sales
2.7
Price/Book
1.9

Growth

Revenue
+12.4%
EPS
+10.5%
Free Cash Flow
+90.1%

Profitability

Gross Margin
53.3%
Operating Margin
17.2%
Net Margin
11.7%
ROE
9.0%
ROIC
7.1%

Balance Sheet

Debt/Equity
0.26
Current Ratio
1.51

Earnings Reports

๐Ÿ“… Next earningsAug 6, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Aug 6, 26
TBD
โ€”
Est 0.16
โ€”
โ€”
Est 1856526.0B
โ€”
โ€”
May 19, 26
โ€”
Est 0.09
โ€”
โ€”
Est 1793632.0B
โ€”
โ€”
May 15, 26
โœ“
0.11
Est 0.09
+19.0%
1891415.0B
Est 1827238.0B
+3.5%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.